Healthcare / Biotech blogs and newsletters worth following, and what each is good for
These are the blogs and newsletters Briefwire has chosen to cover Healthcare / Biotech, each one fetched and checked before it is listed. Company engineering blogs, analyst newsletters and practitioner posts. The receipt is the post it was written in.
The list
In no ranked order. The note beside each says what it is good for, which is a different thing from how big it is.
Each note describes the publication in its own terms. Briefwire reads what these sources publish, in public, and nothing else.
Best-in-class biotech and health-policy reporting; the default industry citation.
Drug-development and pharma-business coverage; trial results and licensing deals.
Digital-health and payer-provider coverage; strong on funding and partnership news.
Provider and payer strategy, M&A and regulation; core US health-system tracking.
Non-profit health-policy journalism; the reference for coverage and cost analysis.
Blake Madden's health-system financial analysis; margin and consolidation detail for consultants.
Long-running commentary from health-policy practitioners and digital-health founders.
Approvals, recalls and enforcement direct from the regulator — the primary dating source.
Pharma R&D and manufacturing trade coverage; platform-technology adoption and CDMO capacity.
Device and drug safety signals from the regulator, ahead of any press coverage.
Structured recall events; the way to track a competitor's quality failures on the record.
Rulemaking and guidance documents from FDA; the earliest dated policy signal.
CDER's own stream of approvals, labeling changes and guidance — narrower and faster than the press-release feed already in the library.
UK medicines and device regulator's announcements — approvals, safety alerts and enforcement; the news stream, not the corporate-report stream.
Payment rules and coverage rulemaking from the largest US payer; reimbursement changes appear here before any trade write-up.
Outbreak declarations, MMWR-linked announcements and agency guidance; cdc.gov itself serves no feed, this syndication API is the one it links.
Preprints land months before journal publication; the earliest dated signal that a platform-technology claim exists at all.
Clinical-AI and EHR-evaluation preprints; the evidence layer under digital-health vendor performance claims.
Open-access clinical research with full text available — unlike the paywalled majors, the article itself is ingestible, not just the abstract.
Epic's own analyses across its de-identified EHR footprint; the largest US clinical dataset publishing findings under its own name.
The health-system-owned data collective publishing its own real-world-evidence studies; useful as the counterweight to pharma-funded RWE.
Consumer-genomics research and policy posts first-party; note the feed now lives on the .org domain after a redirect, not .com.
Trial readouts, approvals and litigation statements from the largest healthcare company, in its own words and dated.
- Drug Channels (Adam Fein)
The single best source on PBM economics, gross-to-net and pharmacy consolidation; one named economist with his reputation on every post.
An Atlas Venture partner writing candidly on biotech financing, startup failure rates and venture returns under his own byline.
Long-form essays on biotechnology's technical frontier by named working scientists; low cadence, so watch it against the six-month rule.
Bioprocessing, tools and genomics trade coverage; the reliable read on instrument and CDMO capacity moves.
Clinical-trial outcomes and pipeline decisions with consistent, dated reporting.
Device makers, FDA clearances and medtech competitive moves; dates the approval race.
Big-pharma pipeline and regulatory announcements first-party; the deepest archive of any pharma feed tested, and all of it dated.
Healthcare business models explained without consultant hedging; the reference read on why a digital-health company actually makes money.
Pharma commercial and R&D-organisation reporting — leadership moves, launch strategy and the people side the pipeline trades skip.
How the list was made, and what we do with it
- Chosen by hand
- Every source is here because people who work in Healthcare / Biotech say substantive things on it, not because it is large. Enough of them to cover the field, few enough to audit.
- Checked before listing
- Each feed is fetched and checked when it is added and again whenever the library is re-checked by hand: one whose newest item is more than six months old fails, and one quiet for more than three is flagged but can stay listed. Every source is English-language and public.
- Read, so you need not
- You do not have to read all of them. Each new post is read, and the claims worth keeping are pulled out, each linked to the post it was written in.
- When it is read
- Briefwire reads a beat’s sources through the day while a trial or paid account tracks it. A beat nobody tracks may not be read at all, and its page shows the library, not a live feed.
- Sent as a brief
- The 12 lines that rank highest across the whole Healthcare / Biotech beat go out daily or weekly. A claim several independent sources made ranks higher — that counts agreement, not accuracy.
The blogs and newsletters are one part of the beat. Every Healthcare / Biotech source, all media — or just the podcasts or changelogs and release feeds.
Run one of these, or think one is missing? How sources are attributed, and how to reach us.
Blogs and newsletters in other industries
- AI Tooling blogs and newsletters
- Dev Tools & Infra blogs and newsletters
- B2B SaaS & GTM blogs and newsletters
- E-commerce / DTC blogs and newsletters
- Fintech & Payments blogs and newsletters
- Crypto & Stablecoins blogs and newsletters
- Cybersecurity blogs and newsletters
- Climate & Energy blogs and newsletters
- Semiconductors / Hardware / Robotics blogs and newsletters
- Legal & RegTech blogs and newsletters
- HR & Future of Work blogs and newsletters
- Insurance & Insurtech blogs and newsletters
- Real Estate & PropTech blogs and newsletters
- Logistics & Supply Chain blogs and newsletters
- Manufacturing & Industrial blogs and newsletters
- Media & Creator Economy blogs and newsletters
- Gaming blogs and newsletters
Terms on this page
Healthcare / Biotech in 12 lines a brief, each with a receipt.
14 days of Desk, every seat, card on file — cancel before the trial ends and the card is never charged.